Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials.

What was studied

This systematic review and meta-analysis looked at oral PCSK9 inhibitors. They are drugs for adults with high cholesterol. The review pooled randomised trials that compared these pills with placebo. The team searched PubMed, Embase and Scopus up to March 2026. The main outcomes were changes in LDL cholesterol and triglycerides. Others included other blood fats, side effects and deaths. Trial quality was rated with RoB2. Certainty was rated with GRADE.

What they found

The trials had 4268 people. LDL cholesterol fell significantly with the drugs. The mean difference was -49.49 mg/dL. Triglycerides also fell significantly, by -11.65 mg/dL. Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell significantly. Total cholesterol fell too. Higher doses gave greater falls. Deaths and overall side effects did not differ significantly. Stopping the drug because of side effects was lower with the drug.

What it means for patients

The authors say the drugs gave meaningful gains in many blood fat measures. They say the short-term safety profile was favourable.

Why it is not certain yet

The authors say the evidence comes mainly from short-term trials. These trials looked at lab measures, not heart outcomes. They say larger trials with longer follow-up and heart outcome data are needed. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials.

We restate facts from the source record in our own words. The original wording belongs to its publisher.